IP Library Granted Patent US 9,283,239
Granted Patent B2
US 9,283,239 · App. 14/635,857 · Granted Mar 15, 2016

Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,283,239
App. No.
14/635,857
Granted
Mar 15, 2016
Kind
B2
Abstract

Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.

Claims (17)

1. A method of treating complex regional pain syndrome comprising orally administering zoledronic acid to a human being in need thereof, wherein the human being receives about 80 to about 500 mg of zoledronic acid within a period of six months.

2. The method of claim 1 , wherein the human being experiences pain relief that lasts for a duration of at least 48 hours, and the human being receives zoledronic acid no more often than once daily.

3. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 30 minutes after the zoledronic acid is administered.

4. The method of claim 1 , wherein zoledronic acid is orally administered for only 1 to 3 months.

5. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 1 hour after the zoledronic acid is administered.

6. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 2 hours after the zoledronic acid is administered.

7. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 1 hour before the zoledronic acid is administered.

8. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 2 hours before the zoledronic acid is administered.

9. The method of claim 1 , wherein the zoledronic acid is orally administered weekly.

10. The method of claim 1 , wherein the zoledronic acid is orally administered weekly for 1 or 2 months.

11. The method of claim 10 , wherein about 10 mg to about 100 mg of zoledronic acid is orally administered weekly.

12. The method of claim 1 , wherein the zoledronic acid is orally administered once a month, or less frequently.

13. The method of claim 1 , wherein the zoledronic acid is orally administered 2 to 5 times in a month.

14. The method of claim 1 , wherein the zoledronic acid is orally administered daily.

15. The method of claim 14 , wherein about 10 mg to about 100 mg of zoledronic acid is orally administered daily.

16. The method of claim 15 , wherein the zoledronic acid is orally administered for 5 to 10 consecutive days.

17. The method of claim 1 , wherein the zoledronic acid is orally administered in a dosage form containing at least 10% zoledronic acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2016
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 039083/0386 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2015
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 036620/0738 →